In the research and development of antibody-drug conjugates (ADC) drugs, pharmacokinetic studies of anti-eribulin payload antibodies are ongoing.
Anti-Eribulin payload antibody in PK study in ADC drug development
Anti-Eribulin antibody used in pharmacokinetic studies to evaluate concentrations of Eribulin and its conjugates in biological matrices with high precision. Eribulin mesylate is a synthetic version of the natural product Halichondrin B, which is derived from the sponge Halichondria okadai; it is mainly used to treat metastatic breast cancer and liposarcoma.
Similar to camptothecin, Eribulin can also be used as a payload in antibody-drug conjugates (ADC), which bind to antibodies targeting cancer cells.
Application
• Competitive immunoassay validation for MMAE payload of antibody-drug conjugates (ADC)
• (Competitive ELISA) and other immunoassays, PK and PD assays
Product Highlights
• Purity: ≥95% (SDS-PAGE)
• Validated high affinity and specificity
• High sensitivity validated by ADC binding assay
MSDS
GeneMedi company's product list of anti-Eribulin antibodies
| Cat No. | Product Description | Fc Type | Details |
|---|---|---|---|
| GTU-Bios-Eribulin-Ab | Anti-Eribulin monoclonal antibody (mAb) | hFc/mFc | Details |
Technical Details
-
Specificity
Anti-Eribulin antibody is a molecule specifically designed to selectively react with Eribulin and its analogs. This specificity is crucial for determining the pharmacokinetic parameters of the entire drug, especially for antibody-drug conjugates (ADC). Due to high measurement precision, free drug and ADC can be analyzed separately via AUC.
-
Sensitivity
These antibodies can be used to detect trace amounts of Eribulin, which is critical for determining therapeutic and toxic concentrations of the drug in vivo, as Eribulin has highly potent and strong cytotoxic effects.
-
Efficacy and safety assessment:
Understanding the pharmacokinetic profile of the drug, especially when conjugated in an antibody-drug conjugate (ADC), is critical for determining the drug's ability to target tumor cells and the rate of payload release in the tumor microenvironment. This assessment is essential for determining the correctness of the treatment approach and patient safety.
-
Development of immunoassay methods:
As mentioned above, anti-eribulin antibodies can be used to prepare different immunoassays, such as enzyme-linked immunosorbent assay (ELISA). These assays can be used to determine the concentration of eribulin in plasma, serum, and other tissues. These assays help determine the biodistribution and clearance of related drugs.
-
Sample Collection and Analysis
Data obtained from pharmacokinetic studies help determine the pharmacokinetic behavior of eribulin and select appropriate dosing regimens. Additionally, these data are crucial for studying drug compatibility with biological systems, assessing potential adverse reactions, and the possibility of achieving optimal therapeutic effects.
-
Data Interpretation and Clinical Application
Data obtained from pharmacokinetic studies help determine the pharmacokinetic behavior of eribulin and select appropriate dosing regimens. Additionally, these data are crucial for studying drug compatibility with biological systems, assessing potential adverse reactions, and the possibility of achieving optimal therapeutic effects.
Pharmacokinetic studies of antibody-drug conjugates (ADCs), the application of anti-eribulin antibodies, and monotherapy all require eribulin as a foundation for new therapy development. It helps bridge knowledge gaps; otherwise, due to inaccurate pharmacokinetic data, cancer patients in the therapeutic development phase may receive ineffective or even dangerous drugs.
Technical Resource
Antibody-Drug Conjugate (ADC) Knowledge Base
- ADC Panorama: Production, Mechanism (MOA), FDA-Approved Antibodies, and Functional Analysis
- What is an Antibody-Drug Conjugate (ADC)?
- ADC Clinical Application Progress (Approved/BLA/Various Clinical Phases)
- ADC Key Components: Antibody and Target
- ADC Key Components: Linker Structure and Mechanism
- ADC Key Components: Toxin/Payload (Classification and Function)
- Payload: Microtubule Disrupting Agents (Classification and Function)
- Payload: DNA Damaging Agents (Classification and Function)
- Payload: Novel Drugs (Classification and Function)
- Bioconjugation Technology: Chemical-Based Site-Specific Modification
- Endogenous Amino Acid Conjugation and Disulfide Rebridging Strategies
- Glycan Coupling
- Engineered Antibody Site-Specific Bioconjugation and Enzymatic Methods
- Bioconjugation of Engineered Unnatural Amino Acids
- Overview of ADC Production, Quality Control, and Functional Analysis
- ADC Product Data
(Talk with our expert for quote)